Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate
|
|
- Ambrose Greer
- 5 years ago
- Views:
Transcription
1 pharmacoepidemiology and drug safety 2012; 21(S2): Published online in Wiley Online Library (wileyonlinelibrary.com).3252 ORIGINAL REPORT Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate Bing Cai 1, Sean Hennessy 2, James H. Flory 3, Daohang Sha 4, Thomas R. Ten Have 2 and Dylan S. Small 5 * 1 Epidemiology Department of Pfizer Inc, 500 Arcola Road, Collegeville, PA, USA 2 Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine Blockley Hall, Philadelphia, PA, USA 3 Division of Endocrinology, Diabetes, and Metabolism in the Department of Medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center, New York Presbyterian Hospital, New York, NY, USA 4 Biostatistics Analysis Center, University of Pennsylvania School of Medicine, Blockley Hall, Philadlephia, PA, USA 5 Department of Statistics, Wharton School, 464 JMHH/6340, University of Pennsylvania, Philadelphia, PA, USA ABSTRACT Purpose We studied the application of the generalized structural mean model (GSMM) of instrumental variable (IV) methods in estimating treatment odds ratios (ORs) for binary outcomes in pharmacoepidemiologic studies and evaluated the bias of GSMM compared to other IV methods. Methods Because of the bias of standard IV methods, including two-stage predictor substitution (2SPS) and two-stage residual inclusion (2SRI) with binary outcomes, we implemented another IV approach based on the GSMM of Vansteelandt and Goetghebeur. We performed simulations under the principal stratification setting and evaluated whether GSMM provides approximately unbiased estimates of the causal OR and compared its bias and mean squared error to that of 2SPS and 2SRI. We then applied different IV methods to a study comparing bezafibrate versus other fibrates on the risk of diabetes. Results Our simulations showed that unlike the standard logistic, 2SPS, and 2SRI procedures, our implementation of GSMM provides an approximately unbiased estimate of the causal OR even under unmeasured confounding. However, for the effect of bezafibrate versus other fibrates on the risk of diabetes, the GSMM and two-stage approaches yielded similarly attenuated and statistically non-significant OR estimates. The attenuation of the OR by the two-stage and GSMM IV approaches suggests unmeasured confounding, although violations of the IV assumptions or differences in the parameters estimated could be playing a role. Conclusion The GSMM IV approach provides approximately unbiased adjustment for unmeasured confounding on binary outcomes when a valid IV is available. Copyright 2012 John Wiley & Sons, Ltd. key words causal inference; instrumental variable; two-stage regression; generalized structural mean model; bezafibrate; diabetes Received 30 July 2011; Revised 7 February 2012; Accepted 8 February 2012 INTRODUCTION Instrumental variable (IV) methods are increasingly used to adjust for unmeasured confounding in pharmacoepidemiology. 1 8 An IV is a variable that is associated with the treatment but is independent of unmeasured confounders and has no direct effect on the outcome. 9 In addition, an IV is often assumed to satisfy a monotonicity condition, i.e., that subjects treatment level increases monotonically with the level of the IV. 9 IVs satisfying the monotonicity condition enable identification of the local average treatment effect (LATE), *Correspondence to: D. Small is Associate Professor, Department of Statistics, Wharton School, 464 JMHH/6340, University of Pennsylvania, Philadelphia, PA dsmall@wharton.upenn.edu deceased i.e., the treatment effect among compliers. Under linear models, two two-stage IV approaches, i.e., two-stage predictor substitution (2SPS) and two-stage residual inclusion (2SRI), have been shown to yield unbiased estimators of the LATE. 9 In 2SPS, a first-stage model is fit to predict the treatment based on the instrument and covariates, and a second-stage model is fit for the mean of the outcome as a function of the predicted value of the treatment from the first stage and the covariates; the estimated LATE is the coefficient on the predicted treatment in the second-stage model. 10 In 2SRI, the first stage is the same as for 2SPS, but the second-stage model is the mean of the outcome as a function of the residual from the first-stage regression, actual value of the treatment, and the covariates; the estimated LATE is the coefficient on the actual Copyright 2012 John Wiley & Sons, Ltd.
2 treatment. 3,11 For continuous outcomes, the 2SPS and 2SRI IV estimators are equivalent. For binary outcomes, the 2SPS and 2SRI IV odds ratio (OR) estimators are not equivalent, and both have been shown to be biased for the LATE when there is strong confounding. 12 An alternative to the biased two-stage IV estimators of the LATE OR is the generalized structural mean model (GSMM), which Vansteelandt and Goetghebeur have shown is a consistent estimator under certain conditions. 1,2 Here, we implemented the GSMM approach such that it allows both levels of a dichotomous IV to have access to the treatment, as is the case in most observational studies, and we evaluated the bias of the method with a simulation study. In addition, we compare different estimators in a study of the effect of bezafibrate on the risk of diabetes. Bezafibrate is a lipid-lowering medication that is widely prescribed in the United Kingdom. Recent published results suggest that the protective effect of bezafibrate against the onset of diabetes is superior to that of other fibrates Flory et al. published a retrospective cohort study using the General Practice Research Database (GPRD) to compare the risk of diabetes between users of bezafibrate versus other fibrates and showed lower incidence of diabetes in bezafibrate users. 18 This analysis controlled for measured confounders but not unmeasured confounders. Inspection of baseline data in the publication by Flory et al. showed statistically significant differences in the prescribing patterns for different fibrates, most notably higher rates of baseline diabetes in patients receiving fenofibrate compared to patients receiving bezafibrate. Although the clinical properties and indications for the fibrates are very similar to one another, this observation suggested that providers might still have subtle prescribing preferences that could introduce unmeasured confounding. To control for this potential unmeasured confounding, we present IV-based results, using the previous prescription from the same practice as the IV; this preference-based IV has been used by other pharmacoepidemiologic studies. 6,19 21 METHODS Notation and assumptions The treatment (bezafibrate) variable is Z : Z = 1 denotes that a patient received the treatment of interest (bezafibrate); and Z = 0 means a patient received an alternative treatment (other fibrate). The IV variable is R : R =1 corresponds to a patient exhibiting level 1 of the IV that predisposes to bezafibrate treatment (practice s previous fibrate prescription was for bezafibrate) and R = 0 to a patient exhibiting level 0 of the IV that simulation study of instrumental variable approaches 115 predisposes to a non-bezafibrate fibrate (practice s previous fibrate prescription was for a different fibrate). The vector of observed baseline confounders will be denoted by X. For the outcome variables, we define Y as the observed outcome: Y = 1 if the patient exhibits the outcome (incident diabetes), and Y = 0 if the patient does not exhibit the outcome (no diabetes). The potential outcome Y (1) is the outcome a patient would exhibit if she/he were to receive bezafibrate; Y (0) is the outcome if the patient were to receive a different fibrate. Under the assumptions below, Y (1) = Y if the patient actually receives bezafibrate; and Y (0) = Y if the patient receives a different fibrate. The potential treatment received Z (1) (Z (0) ) is the treatment level a patient would receive if predisposed (not predisposed) to take bezafibrate by the IV. Subjects can be classified into four compliance classes: (i) alwaystakers of bezafibrate, Z (1) = Z (0) = 1, would always take the fibrate previously prescribed by that practice; (ii) compliers with the suggestion of the IV, Z (1) =1, Z (0) = 0; (iii) defiers take the opposite of what the previous prescription was ( defiers ), Z (1) =0,Z (0) =1; and (iv) never takers of bezafibrate, Z (1) = Z (0) =0. The assumptions of the IV approaches pertain to the relationships among the IV, treatment, and outcome. We make the same five assumptions about an IV as Angrist, Imbens, and Rubin 9 : (i) stable unit treatment value assumption (SUTVA);(ii) random assignment; (iii) exclusion restriction, which means the IV affects the outcome only through the treatment and has no direct effect; (iv) non-zero average causal effect of the IV on treatment; and (v) monotonicity, which means that there are no defiers, as defined above. These assumptions enable identification of the LATE OR, the likelihood of success under treatment compared to control for the compliers. Models Details of the estimation procedure for the GSMM and the two-stage IV procedures are in Appendix I and II. We focus here on the GSMM. The GSMM seeks to estimate o logitfe Y ðþ 1 jx ¼ x; Z ¼ 1; R ¼ rþ logitfeðy ð0þ jx ¼ x; Z ¼ 1; R ¼ rþg ¼ c (1) where c is the causal log OR for the effect of treatment on the risk of the outcome (bezafibrate effect on diabetes risk) among those who received treatment and have IV level r. The causal log OR c in Equation (1) is assumed to not be modified by the IV R; consequently,
3 116 b. cai et al. c is the treatment on treated (TOT) causal log OR, measuring the effect of treatment for those who received treatment. Under the assumptions described in Section 2.1 and the assumption that the causal log OR is not modified by the IV, c is equal to the causal log OR for the effect of treatment for the compliers. 22 Because the nonlinearity of the logistic function distorts integration of the probability model under (1) with respect to treatment Z, which is necessary for estimation, we need to specify an association model for each level of the IV. Such a model is not causal, RESULTS because no parameter corresponds to a causal treatment effect. The association model is specified separately Simulation results for each level of the IV as a standard logistic model for the log OR of treatment on outcome, adjusting for observed covariates and the IV: logit EYX¼ ð j x; Z ¼ z; R ¼ 1Þg ¼ b 11 z þ b T 12 x (2) logit EYX¼ ð j x; Z ¼ z; R ¼ 0Þg ¼ b 01 z þ b T 02 x (3) where the first subscript for the b, log OR parameters indicates the level of the IV within which the logistic models in (2) and (3) are applied. For a clinical trial with controls not having access to treatment, Equation (2) is the only association model, because in the control arm, Z = 0 for all patients, so that one cannot apply the association model in Equation (3). However, for observational studies, Z can be either 0 or 1 for either level of the IV, so we specify the second association model in (3) for the second level of the IV. It is explained in Appendix 1 of the supplementary materials how the structural model and the association model are combined to estimate the causal OR c. SAS macros for implementing the GSMM approach are provided in the Appendix. SIMULATIONS The simulations for evaluating the GSMM, two-stage, and standard logistic approaches require a fully specified (parametric) model to generate the potential outcomes for Y and Z. We simulate data from the compliance class model 9 to serve as the true model, as it is fully parametric and also accommodates the different assumptions that lead to different causal effects (e.g., LATE effect). Appendix III describes the parameters of the compliance class model used to simulate the data. The parameters that we vary in the simulation study include (i) the amount of unmeasured confounding, which is measured by d, the difference on the logit scale in the probability that the outcome is 1 under no treatment between compliers and never-takers; (ii) how frequent the outcome is; and (iii) the strength of the instrument, which is measured by the proportion of compliers. We then analyzed each simulated dataset with the GSMM, twostage, and standard logistic approaches. Our goal is to compare the bias, mean squared error, and confidence interval coverage of the GSMM estimator and compare it to the two-stage estimators. Table 1 presents simulation results when the sample size was 10,000 and there were no always-takers. For a frequent outcome (true risk of outcome is 0.30), the percent absolute bias for the GSMM was very small (less than 0.35%) with no consistent increase with the magnitude of unmeasured confounding. For a rare outcome (true risk of outcome is 0.03), the percent absolute bias was larger than for the common outcome setting, ranging between 1.50% and 11.00%, with an increase in positive bias with the magnitude of confounding. When there was a large amount of unmeasured confounding that biased the estimator upwards, and a difference of 2 on the logit scale in the probability that the outcome is 1 under no treatment between compliers and never-takers, the estimation routine did not converge for 36% of the simulations, which were discarded from the results. Table 2 presents the results of the simulations of sample size 10,000 that include always-takers. Similar to the non-alwaystaker case in Table 1, the bias of the treatment effect estimator was also very small (less than 0.26%) for the frequent outcome. As with the non-always-takers case for the rare outcome, the bias estimated from the simulation was larger than for the frequent outcome setting, but it was still very small (less than 4%). Unlike the situation with the non-always-takers, the magnitude of bias did not increase with the magnitude of confounding with always-takers. In both Table 1 and Table 2, the 95% CI coverage was close to 95%. Table 3 compares bias, variance, and mean squared error of the 2SPS and 2SRI with the GSMM method. In these simulations the sample size is N = 3000, and the proportion of compliers (strength of the instrument) includes 0.3, 0.5, and 0.7. For the GSMM approach, the estimated bias ranged up to 2%. In contrast, the 2SPS and 2SRI are more biased, both ranging above 50%. For these two approaches, bias increased with increased confounding and a weaker instrument (fewer compliers). Comparing the variance of the three approaches, we can see that the GSMM had the smallest and 2SRI the
4 simulation study of instrumental variable approaches 117 Table 1. Simulation results of GSMM estimator without always-takers under different outcome risks and true unmeasured confounding relationships. Outcome Risk d Estimated Log OR 1 Bias Bias(%) Width of 95% CI % Coverage } Note: The sample size is 10,000; for outcome risks of 0.30, the true log OR equals ; and for outcome risk of 0.03, the true log OR equals OR: odds ratio. } Based on the 1275 simulations instead of 2000 simulations because the R program stopped when the model didn t converge or the system was computationally singular. Table 2. Simulation results of GSMM estimator with always-takers under different outcome risks and true unmeasured confounding relationships. Outcome Risk d Estimated Log OR Bias Bias (%) Width of 95% CI % Coverage Note: The sample size is 10,000; for outcome risks of 0.30, the true log OR equals ; and for outcome risk of 0.03, the true log OR equals OR: odds ratio. greatest variance. The GSMM also had the smallest MSE among the three approaches. The results are mixed when comparing the MSE between the 2SRI and 2SPS procedures. Bezafibrate data analysis Following the methods of Flory et al., 18 we defined treatment as the initial fibrate treatment. We defined the IV as the prior prescription from the same practice as the patient. If a patient was the first one in the practice to be prescribed a fibrate, there was no IV defined for this patient, and so that patient was excluded. Using this subset of the data, we followed Flory et al. by performing analyses with and without adjusting for the following covariates: calendar year, age, sex, smoking status, body mass index, hypertension, history of myocardial infarction (MI), history of stroke, use of potentially protective drugs (angiotensin-converting enzyme inhibitors), and common potentially diabetogenic drugs (beta blockers, thiazide diuretics, corticosteroids). 15 The analyses were performed with different IV methods. The assessment of the association between the IV and treatment is presented in Table 4. When the prior fibrate prescription from the same practice was bezafibrate, 79.4% of the patients actually had a bezafibrate prescription. In comparison, when the prior prescription from the same practice was a different fibrate, only 60.7%
5 118 Table 3. b. cai et al. Comparing bias, variance, and MSE of the 2SRI, 2SPS, and GMSS approaches without always-takers. Compliance d 2SPS 2SRI GSMM Bias% Variance MSE Bias% Variance MSE Bias% Variance MSE Note: The sample size is The outcome risk of 0.30 with the true log OR equaling Table 4. Association of the IV with the treatment and outcome. Treatment to bezafibrate (%) OR (95% CI) P-value IV = Bezafibrate 9127 (79.40) 2.49 (2.31, 2.68) < IV = Other fibrates 2648 (60.76) Number of patients with diabetes (%) OR (95% CI) P-value IV = Bezafibrate 216 (1.88) 0.97 (0.76, 1.26) 0.84 IV = Other fibrates 84 (1.93) of patients had a bezafibrate prescription. The OR is 2.49 with 95% confidence interval ( ), indicating a statistically significant association between the IV and treatment. On the other hand, the association of IV and the outcome was very weak, with odds ratio 0.97 (95% CI ), and p value We now consider the association between bezafibrate and diabetes. First, the unadjusted OR of bezafibrate versus other fibrates on the outcome of diabetes in the subset in which an IV could be defined was 0.67 (95% CI ), indicating a strong inverse association. In Table 5, we compare the different estimates of the effect of bezafibrate on diabetes, with and without adjustment of covariates. Under standard logistic regression (corresponding to the above OR based on actual counts), the OR (95% confidence interval) was 0.67 (0.53,0.85) with or without covariates (differences are at the 1000ths place to the right of the decimal). In contrast, the IV-based approaches yielded ORs that were not statistically different from one, which was due to both attenuated ORs and wider confidence intervals. Specifically, the 2SPS, 2SRI, and GSMM approaches yielded very similar estimates without covariates: 0.87 (0.22, 3.41), 0.90 (0.23, 3.53), and 0.82 (0.50,1.35), respectively. However, adjusting for covariates, the GSMM OR 1.50 (0.72, 3.10) differed substantially from the 2SPS and 2SRI ORs of 0.77 (0.19, 3.16) and 0.78 (0.19, 3.21), respectively. However, in all cases, the IV ORs were not statistically different from one. We note that a crucial assumption for the GSMM approach is that each of the separate association models relating outcome to treatment at each level of the IV is specified correctly. None of the covariates that were originally selected
6 simulation study of instrumental variable approaches 119 Table 5. Comparison of results of analysis of bezafibrate versus other fibrates with respect to risk of first diabetes outcome by different estimation approaches with and without covariates 1. Model Covariate(s) Treatment Effect Log OR Standard Error P-value for the treatment effect Standard Logistic Regression No Covariates Covariates IV 2SPS No Covariates Covariates IV 2SRI No Covariates Covariates IV GSMM No Covariates Covariates Covariates include: calendar year, age, sex, smoking status, body mass index, hypertension, history of myocardial infarction, history of stroke, use of potentially protective drugs (angiotensin converting enzyme inhibitors), and common potentially diabetogenic drugs (beta blockers, thiazide diuretics, corticosteroids). by Flory et al. and used in the analysis were associated with the outcome conditional on the level of the IV. Consequently, it is reasonable to use the GSMM estimate that does not adjust for these covariates. Finally, as shown in Table 5, the GSMM standard error was smaller than the standard errors of the 2SPS and 2SRI approaches, as reflected in the narrower confidence intervals of the GSMM ORs. This was consistent with our simulation results. DISCUSSION Under the IV assumptions, the IV approach estimates a causal OR of treatment received (e.g., receiving a prescription for that treatment) among compliers (those who would take the treatment only under encouragement to do by the IV). A standard logistic regression adjusting for observed potential confounders shows a statistically significant inverse association between bezafibrate use and risk of diabetes. However, the different IV approaches yielded statistically nonsignificant associations due both to attenuated ORs and wider confidence intervals. In spite of the consistency among the results of the IV approaches without adjusting for covariates, our simulations suggest that the GSMM approach is less biased and has narrower confidence intervals than the more standard IV two-stage approaches to the logistic regression context. Our implementation of the GSMM approach from its original randomized context (where the control group does not have access to treatment) to the current observational context (where patients with both levels of the IV have access to treatment) performed well in the simulations. We have more confidence in the results of the GSMM approach than in those of the two-stage 2SPS and 2SRI approaches, which have been shown to be biased. 3,12 One does have to be careful with the GSMM approach, given its reliance on the assumption of correct association models for the treatment-outcome association within each level of the IV. Another difficulty with the GSMM approach is that in simulations in which a large amount of unmeasured confounding biased the standard logistic estimator upwards, the estimation routine sometimes did not converge. The IV estimates of the effect of bezafibrate prescriptions on the risk of diabetes, not adjusting for observed covariates, indicate that the statistically significant association identified by the standard approach may be due to unmeasured confounders, given that the different IV estimates were consistently attenuated. The differences between the IV estimates and the standard approach could also be due to the fact that they are estimating effects for different target populations: the standard approach is targeted at the whole population, while the IV estimate is targeted at the compliers. Subpopulations for which the instrument is stronger contain a larger proportion of compliers than the general population. 23 Table 6 shows the strength of instrument in various subpopulations, which indicates that the compliers are more likely to be high-risk patients with a history of MI or stroke. Caution should also be exercised in using the IV analyses for inference in light of the assumptions that are needed for validity. Additionally, while IV analysis can control for unmeasured confounding, it is often has poor statistical precision, which leads to wide confidence intervals. Future research should focus on assessing departures from the above IV assumptions. For continuous outcomes, assessments of the exclusion restriction assumption have been based on incorporating weights into the estimation of the linear model analog to the GSMM, where the weights incorporate baseline covariate-iv interactions that affect the probability of treatment given the IV. 24 Extensions of this approach to the GSMM are being investigated, assuming the IV is unrelated to unmeasured confounders of the treatment-outcome relationship. To assess the
7 120 b. cai et al. Table 6. Strength of the instrument in subgroups defined by observed risk factors. The strength of the instrument is E[Z R =1,S =1] E[Z R =0,S = 1] where S = 1 denotes membership in the subgroup. Subgroup E[Z R = 1,S = 1] E[Z R = 0,S = 1] Instrument Strength Full Population Male Gender History of Myocardial Infarction History of Stroke History of Calcium Channel Blocker Use History of Thiazide Diuretics Use History of Corticosteroids Use History of Beta Blockers Use History of ACE Inhibitors Use assumption that the IV is not related to unmeasured confounders of the treatment-outcome relationship, one can extend the sensitivity analysis strategy of Small for linear models to the logistic case. 25 While our analysis was based on the logistic model, the original paper by Flory et al. used the Cox proportional hazards model. Unfortunately, use of the twostage IV approaches for such a model is also biased for estimation of the LATE and TOT hazard ratios. Methods have been proposed to resolve such bias in the context of randomized trials that are subject to design constraints, such as when one group is not measured for the treatment-received variable. These methods are challenging to implement and have limitations with the corresponding estimation procedures. 26 CONFLICT OF INTEREST The authors declare no conflict of interest. KEY POINTS Instrumental variable methods provide a way of estimating the causal effect of treatment when there is unmeasured confounding but a valid instrumental variable can be found. A simulation study shows that the generalized structural mean model estimator provides an approximately unbiased estimate of the causal odds ratio when there is a valid instrumental variable, but the two state logistic regression and two stage residual inclusion estimators are biased. A SAS macro is provided for the generalized structural mean model estimator. REFERENCES 1. Goetghebeur E, Vansteelandt S. Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of treatment. Stat Methods Med Res 2005; 14: Vansteelandt S, Goetghebeur E. Causal Inference with generalized structural mean models. J Roy Stat Soc B 2003; 65: Nagelkerke N. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 2000; 19(6): Johnston KM, Gustafson P, Levy AR, Grootendorst P. Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Stat Med 2008; 27: Wang P, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New Engl J Med 2005; 353: Brooks JM, Chrischilles EA. Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods. Med Care 2007; 45: S123 S Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297: Basu A, Heckman JJ, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Econ 2007; 16: Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: Terza JV. Parametric Nonlinear Regression with Endogenous Switching. Econometric Rev 2009; 28(6): Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. J Health Econ 2008; 27(3): Cai B, Small DS, Ten Have T. Bias of Causal Inference for the Odds Ratio Using Two-stage Instrumental Variable Methods. Stat Med 2011; 30: Tenenbaum A, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: Tenenbaum A, Fisman EZ, Boyko V, et al. Bezafibrate averts progression of insulin resistance in diabetic patients with coronary artery disease. Eur Heart J 2006; 27: Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005; 26: Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109: Fernandes-Santos C, Carneiro RE, Mendonca LD, et al. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 2009; 25: Flory JH, Ellenberg S, Szapary PO, et al. Antidiabetic Action of Bezafibrate in a Large Observational Database. Diabetes Care 2009; 32: Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: Hennessy S, Leonard CE, Palumbo CM, et al. Instantaneous preference was a stronger instrumental variable than 3-and 6-month prescribing preference for NSAIDs. J Clin Epidemiol 2008; 61: Korn EL, Teeter DM, Baumrind S. Using explicit clinician preferences in nonrandomized study designs. J Stat Plann Infer 2001; 96: Hernan MA, Robins JM. Instruments for causal inference An epidemiologist s dream? Epidemiology 2006; 17: Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostatist 2007; 3(1): Ten Have TR, Joffe MM, Lynch K, Brown G, Maistro S, Beck A. Causal mediation analyses with rank preserving models. Biometrics 2007; 63: Small D. Sensitivity analysis for instrumental variables regression with overidentifying restrictions. J Am Stat Assoc 2007; 102: Odondi L, McNamee R. Performance of statistical methods for analyzing survival data in the presence of non-random compliance. Stat Med 2010; 29:
Brief introduction to instrumental variables. IV Workshop, Bristol, Miguel A. Hernán Department of Epidemiology Harvard School of Public Health
Brief introduction to instrumental variables IV Workshop, Bristol, 2008 Miguel A. Hernán Department of Epidemiology Harvard School of Public Health Goal: To consistently estimate the average causal effect
More informationMediation Analysis With Principal Stratification
University of Pennsylvania ScholarlyCommons Statistics Papers Wharton Faculty Research 3-30-009 Mediation Analysis With Principal Stratification Robert Gallop Dylan S. Small University of Pennsylvania
More informationPropensity score methods to adjust for confounding in assessing treatment effects: bias and precision
ISPUB.COM The Internet Journal of Epidemiology Volume 7 Number 2 Propensity score methods to adjust for confounding in assessing treatment effects: bias and precision Z Wang Abstract There is an increasing
More informationIdentification of population average treatment effects using nonlinear instrumental variables estimators : another cautionary note
University of Iowa Iowa Research Online Theses and Dissertations Fall 2014 Identification of population average treatment effects using nonlinear instrumental variables estimators : another cautionary
More informationDichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods
Merrill and McClure Trials (2015) 16:523 DOI 1186/s13063-015-1044-z TRIALS RESEARCH Open Access Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationComplier Average Causal Effect (CACE)
Complier Average Causal Effect (CACE) Booil Jo Stanford University Methodological Advancement Meeting Innovative Directions in Estimating Impact Office of Planning, Research & Evaluation Administration
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationCan you guarantee that the results from your observational study are unaffected by unmeasured confounding? H.Hosseini
Instrumental Variable (Instrument) applications in Epidemiology: An Introduction Hamed Hosseini Can you guarantee that the results from your observational study are unaffected by unmeasured confounding?
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and
More informationDylan Small Department of Statistics, Wharton School, University of Pennsylvania. Based on joint work with Paul Rosenbaum
Instrumental variables and their sensitivity to unobserved biases Dylan Small Department of Statistics, Wharton School, University of Pennsylvania Based on joint work with Paul Rosenbaum Overview Instrumental
More informationUsing Ensemble-Based Methods for Directly Estimating Causal Effects: An Investigation of Tree-Based G-Computation
Institute for Clinical Evaluative Sciences From the SelectedWorks of Peter Austin 2012 Using Ensemble-Based Methods for Directly Estimating Causal Effects: An Investigation of Tree-Based G-Computation
More informationInstrumental Variable Analysis for Estimation of Treatment Effects With Dichotomous Outcomes
American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationRole of Pharmacoepidemiology in Drug Evaluation
Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is
More informationPropensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy Research
2012 CCPRC Meeting Methodology Presession Workshop October 23, 2012, 2:00-5:00 p.m. Propensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy
More informationAntidiabetic Action of Bezafibrate in a Large Observational Database
Diabetes Care Publish Ahead of Print, published online January 8, 2009 Bezafibrate for Prevention of Diabetes Antidiabetic Action of Bezafibrate in a Large Observational Database James H Flory BA*, Susan
More informationChapter 10. Considerations for Statistical Analysis
Chapter 10. Considerations for Statistical Analysis Patrick G. Arbogast, Ph.D. (deceased) Kaiser Permanente Northwest, Portland, OR Tyler J. VanderWeele, Ph.D. Harvard School of Public Health, Boston,
More informationPropensity scores: what, why and why not?
Propensity scores: what, why and why not? Rhian Daniel, Cardiff University @statnav Joint workshop S3RI & Wessex Institute University of Southampton, 22nd March 2018 Rhian Daniel @statnav/propensity scores:
More informationDetection of Unknown Confounders. by Bayesian Confirmatory Factor Analysis
Advanced Studies in Medical Sciences, Vol. 1, 2013, no. 3, 143-156 HIKARI Ltd, www.m-hikari.com Detection of Unknown Confounders by Bayesian Confirmatory Factor Analysis Emil Kupek Department of Public
More informationConfounding and Bias
28 th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Barcelona, Spain August 22, 2012 Confounding and Bias Tobias Gerhard, PhD Assistant Professor, Ernest Mario School
More informationIdentification of effectheterogeneity. instrumental variables
Identification of effectheterogeneity using instrumental variables Anirban Basu University of Washington, Seattle and NBER Symposium on OBSERVATIONAL STUDIES IN A LEARNING HEALTH SYSTEM April 25, 2013
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationPubH 7405: REGRESSION ANALYSIS. Propensity Score
PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationOptimal full matching for survival outcomes: a method that merits more widespread use
Research Article Received 3 November 2014, Accepted 6 July 2015 Published online 6 August 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.6602 Optimal full matching for survival
More informationComparison And Application Of Methods To Address Confounding By Indication In Non- Randomized Clinical Studies
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses 1911 - February 2014 Dissertations and Theses 2013 Comparison And Application Of Methods To Address Confounding By Indication
More informationInstrumental Variables Estimation: An Introduction
Instrumental Variables Estimation: An Introduction Susan L. Ettner, Ph.D. Professor Division of General Internal Medicine and Health Services Research, UCLA The Problem The Problem Suppose you wish to
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Svanström H, Pasternak B, Hviid A. Use of azithromycin and
More informationAdvanced IPD meta-analysis methods for observational studies
Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationPerformance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study
pharmacoepidemiology and drug safety (2014) Published online in Wiley Online Library (wileyonlinelibrary.com).3724 ORIGINAL REPORT Performance of prior event rate ratio adjustment method in pharmacoepidemiology:
More informationFlexible Matching in Case-Control Studies of Gene-Environment Interactions
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 59, No. Printed in U.S.A. DOI: 0.093/aje/kwg250 ORIGINAL CONTRIBUTIONS Flexible
More informationAssessing the impact of unmeasured confounding: confounding functions for causal inference
Assessing the impact of unmeasured confounding: confounding functions for causal inference Jessica Kasza jessica.kasza@monash.edu Department of Epidemiology and Preventive Medicine, Monash University Victorian
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationBounding the per-protocol effect in randomized trials: an application to colorectal cancer screening
Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening The Harvard community has made this article openly available. Please share how this access benefits
More informationStatistical Techniques for Analyzing Data From Prevention Trials: Treatment of No-Shows Using Rubin's Causal Model
Psychological Methods 1998, Vol. 3, No. 2,147-159 Copyright 1998 by the American Psychological Association, Inc. 1082-989X/98/$3.00 Statistical Techniques for Analyzing Data From Prevention Trials: Treatment
More informationAnalyzing diastolic and systolic blood pressure individually or jointly?
Analyzing diastolic and systolic blood pressure individually or jointly? Chenglin Ye a, Gary Foster a, Lisa Dolovich b, Lehana Thabane a,c a. Department of Clinical Epidemiology and Biostatistics, McMaster
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationBias in regression coefficient estimates when assumptions for handling missing data are violated: a simulation study
STATISTICAL METHODS Epidemiology Biostatistics and Public Health - 2016, Volume 13, Number 1 Bias in regression coefficient estimates when assumptions for handling missing data are violated: a simulation
More informationCAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?
CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? Mette Nørgaard, Professor, MD, PhD Department of Clinical Epidemiology Aarhus Universitety Hospital Aarhus, Denmark Danish Medical Birth Registry
More informationPropensity scores and instrumental variables to control for confounding. ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD
Propensity scores and instrumental variables to control for confounding ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD WP2 WG2: aims Evaluate methods to control for observed and unobserved
More informationMendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates
Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates arxiv:1804.05545v1 [stat.me] 16 Apr 2018 Stephen Burgess 1,2 Jeremy A Labrecque 3 1 MRC Biostatistics
More informationin Medicine Tutorial in Biostatistics: Instrumental Variable Methods for Causal Inference
Received XXXX Statistics (www.interscience.wiley.com) DOI: 10.1002/sim.0000 Research Article in Medicine Tutorial in Biostatistics: Instrumental Variable Methods for Causal Inference Michael Baiocchi a,jing
More informationINTERNAL VALIDITY, BIAS AND CONFOUNDING
OCW Epidemiology and Biostatistics, 2010 J. Forrester, PhD Tufts University School of Medicine October 6, 2010 INTERNAL VALIDITY, BIAS AND CONFOUNDING Learning objectives for this session: 1) Understand
More informationBeyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies
September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia
More informationMethods for Addressing Selection Bias in Observational Studies
Methods for Addressing Selection Bias in Observational Studies Susan L. Ettner, Ph.D. Professor Division of General Internal Medicine and Health Services Research, UCLA What is Selection Bias? In the regression
More informationReceived: 14 April 2016, Accepted: 28 October 2016 Published online 1 December 2016 in Wiley Online Library
Research Article Received: 14 April 2016, Accepted: 28 October 2016 Published online 1 December 2016 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.7171 One-stage individual participant
More informationInstrumental variable (IV) analysis is increasingly used in
Original Article Physician s Prescribing Preference as an Instrumental Variable Exploring Assumptions Using Survey Data Anna G. C. Boef, a Saskia le Cessie, a,b Olaf M. Dekkers, a,c,d Peter Frey, e Patricia
More informationThe Australian longitudinal study on male health sampling design and survey weighting: implications for analysis and interpretation of clustered data
The Author(s) BMC Public Health 2016, 16(Suppl 3):1062 DOI 10.1186/s12889-016-3699-0 RESEARCH Open Access The Australian longitudinal study on male health sampling design and survey weighting: implications
More informationPropensity Score Analysis Shenyang Guo, Ph.D.
Propensity Score Analysis Shenyang Guo, Ph.D. Upcoming Seminar: April 7-8, 2017, Philadelphia, Pennsylvania Propensity Score Analysis 1. Overview 1.1 Observational studies and challenges 1.2 Why and when
More information11/18/2013. Correlational Research. Correlational Designs. Why Use a Correlational Design? CORRELATIONAL RESEARCH STUDIES
Correlational Research Correlational Designs Correlational research is used to describe the relationship between two or more naturally occurring variables. Is age related to political conservativism? Are
More informationApplication of Propensity Score Models in Observational Studies
Paper 2522-2018 Application of Propensity Score Models in Observational Studies Nikki Carroll, Kaiser Permanente Colorado ABSTRACT Treatment effects from observational studies may be biased as patients
More informationA COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY
A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,
More informationPeter C. Austin Institute for Clinical Evaluative Sciences and University of Toronto
Multivariate Behavioral Research, 46:119 151, 2011 Copyright Taylor & Francis Group, LLC ISSN: 0027-3171 print/1532-7906 online DOI: 10.1080/00273171.2011.540480 A Tutorial and Case Study in Propensity
More informationCatherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1
Welch et al. BMC Medical Research Methodology (2018) 18:89 https://doi.org/10.1186/s12874-018-0548-0 RESEARCH ARTICLE Open Access Does pattern mixture modelling reduce bias due to informative attrition
More informationChoice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias
Technical appendix Choice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias Choice of axis in funnel plots Funnel plots were first used in educational research and psychology,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationInstrumental Variables I (cont.)
Review Instrumental Variables Observational Studies Cross Sectional Regressions Omitted Variables, Reverse causation Randomized Control Trials Difference in Difference Time invariant omitted variables
More informationInverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.
Paper SP02 Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. José Luis Jiménez-Moro (PharmaMar, Madrid, Spain) Javier Gómez (PharmaMar, Madrid, Spain) ABSTRACT
More informationImputation approaches for potential outcomes in causal inference
Int. J. Epidemiol. Advance Access published July 25, 2015 International Journal of Epidemiology, 2015, 1 7 doi: 10.1093/ije/dyv135 Education Corner Education Corner Imputation approaches for potential
More informationRandomized experiments vs. Propensity scores matching: a Meta-analysis.
Randomized experiments vs. Propensity scores matching: a Meta-analysis. Antonio Olmos Priyalatha Govindasamy Research Methods and Statistics University of Denver American Evaluation Association Conference
More informationA Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases
A Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases Lawrence McCandless lmccandl@sfu.ca Faculty of Health Sciences, Simon Fraser University, Vancouver Canada Summer 2014
More informationSample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome
Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome Stephen Burgess July 10, 2013 Abstract Background: Sample size calculations are an
More informationEvaluating health management programmes over time: application of propensity score-based weighting to longitudinal datajep_
Journal of Evaluation in Clinical Practice ISSN 1356-1294 Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal datajep_1361 180..185 Ariel
More informationUniversity of Pennsylvania
University of Pennsylvania UPenn Biostatistics Working Papers Year 2005 Paper 1 Casual Mediation Analyses with Structural Mean Models Thomas R. TenHave Marshall Joffe Kevin Lynch Greg Brown Stephen Maisto
More informationIntroducing a SAS macro for doubly robust estimation
Introducing a SAS macro for doubly robust estimation 1Michele Jonsson Funk, PhD, 1Daniel Westreich MSPH, 2Marie Davidian PhD, 3Chris Weisen PhD 1Department of Epidemiology and 3Odum Institute for Research
More informationConfounding by indication developments in matching, and instrumental variable methods. Richard Grieve London School of Hygiene and Tropical Medicine
Confounding by indication developments in matching, and instrumental variable methods Richard Grieve London School of Hygiene and Tropical Medicine 1 Outline 1. Causal inference and confounding 2. Genetic
More informationPropensity Score Methods to Adjust for Bias in Observational Data SAS HEALTH USERS GROUP APRIL 6, 2018
Propensity Score Methods to Adjust for Bias in Observational Data SAS HEALTH USERS GROUP APRIL 6, 2018 Institute Institute for Clinical for Clinical Evaluative Evaluative Sciences Sciences Overview 1.
More informationCausal Mediation Analysis with the CAUSALMED Procedure
Paper SAS1991-2018 Causal Mediation Analysis with the CAUSALMED Procedure Yiu-Fai Yung, Michael Lamm, and Wei Zhang, SAS Institute Inc. Abstract Important policy and health care decisions often depend
More informationChapter 11: Advanced Remedial Measures. Weighted Least Squares (WLS)
Chapter : Advanced Remedial Measures Weighted Least Squares (WLS) When the error variance appears nonconstant, a transformation (of Y and/or X) is a quick remedy. But it may not solve the problem, or it
More informationAn Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Multivariate Behavioral Research, 46:399 424, 2011 Copyright Taylor & Francis Group, LLC ISSN: 0027-3171 print/1532-7906 online DOI: 10.1080/00273171.2011.568786 An Introduction to Propensity Score Methods
More informationChapter 13 Estimating the Modified Odds Ratio
Chapter 13 Estimating the Modified Odds Ratio Modified odds ratio vis-à-vis modified mean difference To a large extent, this chapter replicates the content of Chapter 10 (Estimating the modified mean difference),
More informationEstimating average treatment effects from observational data using teffects
Estimating average treatment effects from observational data using teffects David M. Drukker Director of Econometrics Stata 2013 Nordic and Baltic Stata Users Group meeting Karolinska Institutet September
More informationPHA 6935 ADVANCED PHARMACOEPIDEMIOLOGY
PHA 6935 ADVANCED PHARMACOEPIDEMIOLOGY Course Description: PHA6935 is a graduate level course that is structured as an interactive discussion of selected readings based on topics in contemporary pharmacoepidemiology
More informationChallenges of Observational and Retrospective Studies
Challenges of Observational and Retrospective Studies Kyoungmi Kim, Ph.D. March 8, 2017 This seminar is jointly supported by the following NIH-funded centers: Background There are several methods in which
More informationBias reduction with an adjustment for participants intent to dropout of a randomized controlled clinical trial
ARTICLE Clinical Trials 2007; 4: 540 547 Bias reduction with an adjustment for participants intent to dropout of a randomized controlled clinical trial Andrew C Leon a, Hakan Demirtas b, and Donald Hedeker
More informationComparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators
Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators The Harvard community has made this article openly available. Please share
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationOHDSI Tutorial: Design and implementation of a comparative cohort study in observational healthcare data
OHDSI Tutorial: Design and implementation of a comparative cohort study in observational healthcare data Faculty: Martijn Schuemie (Janssen Research and Development) Marc Suchard (UCLA) Patrick Ryan (Janssen
More information11/24/2017. Do not imply a cause-and-effect relationship
Correlational research is used to describe the relationship between two or more naturally occurring variables. Is age related to political conservativism? Are highly extraverted people less afraid of rejection
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationLive WebEx meeting agenda
10:00am 10:30am Using OpenMeta[Analyst] to extract quantitative data from published literature Live WebEx meeting agenda August 25, 10:00am-12:00pm ET 10:30am 11:20am Lecture (this will be recorded) 11:20am
More informationA Guide to Quasi-Experimental Designs
Western Kentucky University From the SelectedWorks of Matt Bogard Fall 2013 A Guide to Quasi-Experimental Designs Matt Bogard, Western Kentucky University Available at: https://works.bepress.com/matt_bogard/24/
More informationDemystifying causal inference in randomised trials
Demystifying causal inference in randomised trials Ian White 1, Sabine Landau 2, Graham Dunn 3,4 and Richard Emsley 3,4 1 MRC Biostatistics Unit Cambridge 2 Department of Biostatistics, Institute of Psychiatry,
More informationTitle:Bounding the Per-Protocol Effect in Randomized Trials: An Application to Colorectal Cancer Screening
Author's response to reviews Title:Bounding the Per-Protocol Effect in Randomized Trials: An Application to Colorectal Cancer Screening Authors: Sonja A Swanson (sswanson@hsph.harvard.edu) Oyvind Holme
More informationBayesian versus maximum likelihood estimation of treatment effects in bivariate probit instrumental variable models
Bayesian versus maximum likelihood estimation of treatment effects in bivariate probit instrumental variable models Florian M. Hollenbach Department of Political Science Texas A&M University Jacob M. Montgomery
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationPresenter Disclosure Information
Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES
More informationMendelian Randomisation and Causal Inference in Observational Epidemiology. Nuala Sheehan
Mendelian Randomisation and Causal Inference in Observational Epidemiology Nuala Sheehan Department of Health Sciences UNIVERSITY of LEICESTER MRC Collaborative Project Grant G0601625 Vanessa Didelez,
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationAn introduction to instrumental variable assumptions, validation and estimation
https://doi.org/10.1186/s12982-018-0069-7 Emerging Themes in Epidemiology RESEARCH ARTICLE Open Access An introduction to instrumental variable assumptions, validation and estimation Mette Lise Lousdal
More informationGeneralizing the right question, which is?
Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies
More informationbreast cancer; relative risk; risk factor; standard deviation; strength of association
American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationSupplement 2. Use of Directed Acyclic Graphs (DAGs)
Supplement 2. Use of Directed Acyclic Graphs (DAGs) Abstract This supplement describes how counterfactual theory is used to define causal effects and the conditions in which observed data can be used to
More informationRise of the Machines
Rise of the Machines Statistical machine learning for observational studies: confounding adjustment and subgroup identification Armand Chouzy, ETH (summer intern) Jason Wang, Celgene PSI conference 2018
More informationEffects of propensity score overlap on the estimates of treatment effects. Yating Zheng & Laura Stapleton
Effects of propensity score overlap on the estimates of treatment effects Yating Zheng & Laura Stapleton Introduction Recent years have seen remarkable development in estimating average treatment effects
More informationCAUSAL EFFECT HETEROGENEITY IN OBSERVATIONAL DATA
CAUSAL EFFECT HETEROGENEITY IN OBSERVATIONAL DATA ANIRBAN BASU basua@uw.edu @basucally Background > Generating evidence on effect heterogeneity in important to inform efficient decision making. Translate
More informationMortality following acute myocardial infarction (AMI) in
In-Hospital Mortality Among Patients With Type 2 Diabetes Mellitus and Acute Myocardial Infarction: Results From the National Inpatient Sample, 2000 2010 Bina Ahmed, MD; Herbert T. Davis, PhD; Warren K.
More information